Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing

References

• Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics. CA Cancer J Clin. 2017;67:177–193. Internet. doi:10.3322/caac.21395.
   PubMed Web of Science ®Google Scholar
• Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015;33:1809–1824. Internet. doi:10.1200/JCO.2014.59.7633.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345. Internet. doi:10.1056/NEJMoa033025
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342. Internet. doi:10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495–501. Internet. doi:10.1038/nature12912.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data: figure 1. Cancer Discov. 2012;2:401–404. Internet. doi:10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Jang IS, Bot B, Friend S, Guinney J. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov. 2015;5:118–123. Internet. doi:10.1158/2159-8290.CD-14-1118.
   PubMed Web of Science ®Google Scholar
• Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer. 2015;15:311–316. Internet. doi:10.1038/nrc3944.
   PubMed Web of Science ®Google Scholar
• Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015;5:832–841. Internet. doi:10.1158/2159-8290.CD-14-1211
   PubMed Web of Science ®Google Scholar
• Johansen Taber KA, Dickinson BD, Wilson M. The promise and challenges of next-generation genome sequencing for clinical care. JAMA Intern Med. 2014;174:275. Internet. doi:10.1001/jamainternmed.2013.12048.
   PubMed Web of Science ®Google Scholar
• Biesecker LG. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet Med Internet. 2012;14:393–398. http://www.nature.com/articles/gim201178.
   PubMed Web of Science ®Google Scholar
• Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer Internet. 2015;15:747–756. http://www.nature.com/articles/nrc4015.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011;10:1311–1316. Internet. doi:10.1158/1535-7163.MCT-11-0233.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Paz K, Schwartz GK, Wexler LH, Maki R, Pollock RE, Morris R, Cohen R, Shankar A, Blackman G, et al. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer. 2014;120:2006–2015. Internet. doi:10.1002/cncr.28696
   PubMed Web of Science ®Google Scholar
• Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. Internet 2006;12:4652–4661. doi:10.1158/1078-0432.CCR-06-0113.
   PubMed Web of Science ®Google Scholar
• Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto DD, Prasath A, Shanthappa BU, et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015;6:6169. Internet. doi:10.1038/ncomms7169
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. Internet. doi:10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. Internet. doi:10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Ross JS, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio J-A, Ramkissoon S, Severson EA, Daniel S, Fabrizio D, et al. Targeted therapy for HER2 driven colorectal cancer. J Clin Oncol. 2017;35:3583. Internet. doi:10.1200/JCO.2017.35.15_suppl.3583
   Google Scholar
• Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, et al. A molecularly annotated platform of patient- derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508–523. doi:10.1158/2159-8290.CD-11-0109.
   PubMed Web of Science ®Google Scholar
• Siena S, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K, Leone F, Zagonel V, Valtorta E, Torri V, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial. J Clin Oncol. 2015;33:3508. Internet. doi:10.1200/jco.2015.33.15_suppl.3508
   Google Scholar
• Grothey A, Van CE, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312. Internet. doi:10.1016/S0140-6736(12)61900-X
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–1919. Internet. doi:10.1056/NEJMoa1414325
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu R-H, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen Z, Zhong H, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer. JAMA. 2018;319:2486. Internet. doi:10.1001/jama.2018.7855
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. EGF–ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505. Internet. doi:10.1038/nrm1962.
   PubMed Web of Science ®Google Scholar